And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.

Scott Reents Biography and Net Worth

Sr. VP & CFO of AbbVie

Scott Reents is Senior Vice President, Chief Financial Officer, responsible for global financial and business technology operations of the company. He previously served as Vice President, Tax and Treasury.

Mr. Reents joined Abbott in 2008 and held various leadership positions in the company, ultimately serving as Division Vice President, Corporate Tax. After AbbVie’s separation from Abbott in 2013, Mr. Reents led the tax function as Vice President, Tax.

Prior to joining Abbott, Mr. Reents worked in the finance organizations of Pfizer and Pharmacia and began his career at Deloitte.

He earned a bachelor’s degree in finance and economics from the University of Nebraska as well as a Juris Doctor and Master of Business Administration from Washington University.

How old is Scott T. Reents?: Mr. Reents is currently 56 years old. There are 7 older executives and no younger executives at AbbVie. The oldest executive at AbbVie is Mr. Richard A. Gonzalez, Chairman & CEO, who is 70 years old. Learn More on Scott T. Reents' age.
How do I contact Scott T. Reents?: The corporate mailing address for Mr. Reents and other AbbVie executives is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. AbbVie can also be reached via phone at (847) 932-7900. Learn More on Scott T. Reents' contact information.
Has Scott T. Reents been buying or selling shares of AbbVie?: Scott T. Reents has not been actively trading shares of AbbVie during the last quarter. Learn More on Scott T. Reents' trading history.
Who are AbbVie's active insiders?: AbbVie's insider roster includes Carlos Alban (Vice Chairman), Roxanne Austin (Director), Kevin Buckbee (SVP), Nicholas Donoghoe (SVP), Brian Durkin (VP), Richard Gonzalez (CEO), Henry Gosebruch (EVP), Robert Michael (Vice Chairman), Scott Reents (Sr. VP & CFO ), Scott Reents (CFO), Timothy Richmond (EVP), Azita Saleki-Gerhardt (EVP), Laura Schumacher (Vice Chairman), Michael Severino (Vice Chairman), Perry Siatis (EVP), Elaine Sorg (SVP), Jeffrey Stewart (EVP), and Carrie Strom (SVP). Learn More on AbbVie's active insiders.
Are insiders buying or selling shares of AbbVie?: During the last year, insiders at the sold shares 12 times. They sold a total of 410,866 shares worth more than $72,001,272.24. The most recent insider tranaction occured on March, 20th when EVP Nicholas Donoghoe sold 21,082 shares worth more than $3,716,756.60. Insiders at AbbVie own 0.3% of the company. Learn More about insider trades at AbbVie.
Information on this page was last updated on 3/20/2024.

Scott T. Reents Insider Trading History at AbbVie

Scott T. Reents Buying and Selling Activity at AbbVie

AbbVie Company Overview

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Today's Range

Now: $167.29

$165.57

$169.29

50 Day Range

MA: $175.13

$161.67

$182.10

2 Week Range

Now: $167.29

$130.96

$182.89

Volume

5,448,982 shs

Average Volume

5,594,160 shs

Market Capitalization

$296.21 billion

P/E Ratio

61.28

Dividend Yield

3.66%

Beta

0.58

He Is Giving Away Bitcoin

From Crypto Swap Profits | Ad

>> Register right here